The effects of low-dose Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function
Open Access
- 1 August 2012
- journal article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 11 (1) , 90
Abstract
Background: Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD). Endothelial progenitor cell (EPCs) dysfunction plays a key role in this pathogenesis. Uremic retention toxins have been reported to be in associated with EPC dysfunction. Advanced glycation end-products (AGEs) free adducts, including Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-(carboxyethyl)lysine (CEL), are formed by physiological proteolysis of AGEs and released into plasma for urinary excretion. They are retained in CKD patients and are considered to be potential uremic toxins. Though AGEs have been demonstrated to impair EPC function in various ways, the effect of AGE free adducts on EPC function has not been studied. Thus, we examined the role of CML and CEL in the regulation of growth-factor-dependent function in cultured human EPCs and the mechanisms by which they may affect EPC function. Methods: Late outgrowth EPCs were incubated with different concentrations of CML or CEL for up to 72 hours. Cell proliferation was determined using WST-1 and BrdU assays. Cell apoptosis was tested with annexin V staining. Migration and tube formation assays were used to evaluate EPC function. Results: Though CML and CEL were determined to have anti-proliferative effects on EPCs, cells treated with concentrations of CML and CEL in the range found in CKD patients had no observable impairment on migration or tube formation. CML and CEL did not induce EPC apoptosis. The reduced growth response was accompanied by significantly less phosphorylation of mitogen-activated protein kinases (MAPKs). Conclusions: Our study revealed that CML and CEL at uremic concentrations have low biological toxicity when separately tested. The biologic effects of AGE free adducts on the cardiovascular system merit further study.Keywords
This publication has 57 references indexed in Scilit:
- Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cellsCardiovascular Diabetology, 2012
- Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated Type 1 DiabetesCardiovascular Diabetology, 2011
- Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cellsCardiovascular Diabetology, 2010
- The RAGE AxisCirculation Research, 2010
- Endothelial Progenitor Cells and Endothelial Vesicles – What Is the Significance for Patients with Chronic Kidney Disease?Blood Purification, 2010
- Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2Biochemical and Biophysical Research Communications, 2009
- Serum Carboxymethyl-Lysine, an Advanced Glycation End Product, Is Associated With Increased Aortic Pulse Wave Velocity in AdultsAmerican Journal of Hypertension, 2009
- Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patientsAmino Acids, 2007
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003